Filing Flows › Elite Pharmaceuticals (ELTP) › Q4 FY26
Elite Pharmaceuticals (ELTP) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Jun 29, 2026
Elite Pharmaceuticals (ELTP) reported revenue of $40.7M for the fourth quarter fiscal 2026 (Q4 FY26), +27% from a year earlier and +29% from the quarter before. Operating margin was 25.0%, net earnings $18.5M (45.3% of revenue).
Elite Pharmaceuticals, Q4 FY26: revenue $40.7M (+27% year over year), operating margin 25.0%, net earnings $18.5M, operating cash flow $9.1M. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $40.7M | +29% | +27% |
| Gross profit | $20.8M | +60% | +20% |
| Operating profit | $10.2M | +13% | -9% |
| Net earnings | $18.5M | -0.7% | +9% |
| Operating cash flow | $9.1M | — | +133% |
| Free cash flow | $8.7M | — | +177% |
What changed
Revenue was $40.7M in Q4 FY26, up 27% year over year and up 29% from the previous quarter. Manufacturing was the largest line at 99% of revenue.
Gross margin was 51.0%, down 3.1 points from Q4 FY25. Operating profit was $10.2M, a 25.0% margin (down 9.9 points year over year). Operating profit fell $1.0M even though revenue rose $8.8M versus Q4 FY25, so costs grew faster than sales. Operating expenses grew 72% against revenue growth of 27%. The fastest-growing cost line was General & admin (+278%). Net earnings were $18.5M, up 9% year over year. The effective tax rate was 11.5%. Non-operating items added $10.7M, 51% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $9.1M (up 133% year over year), 50% of net earnings. Non-cash charges added back $252K of depreciation and amortization and $29K of share-based compensation. Working capital and other items used $9.6M. Capital expenditures of $398K left free cash flow of $8.7M.
Questions
What was Elite Pharmaceuticals' revenue in the fourth quarter fiscal 2026?
Elite Pharmaceuticals (ELTP) reported revenue of $40.7M for the fourth quarter fiscal 2026 (Q4 FY26), +27% from a year earlier and +29% from the quarter before.
Was Elite Pharmaceuticals profitable in the fourth quarter fiscal 2026?
Operating profit was $10.2M (25.0% of revenue) and net earnings $18.5M.